CSBR - Champions Oncology Inc Stock Price, Fair Value and News

$6.01-0.05 (-0.83%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CSBR Price Action

Last 7 days

-7.5%

Last 30 days

-11.6%

Last 90 days

-13.1%

Trailing 12 Months

39.1%

CSBR RSI Chart

CSBR Valuation

Market Cap

82.9M

Price/Earnings (Trailing)

28.07

Price/Sales (Trailing)

1.46

EV/EBITDA

16.53

Price/Free Cashflow

11.45

CSBR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CSBR Fundamentals

CSBR Revenue

Revenue (TTM)

56.9M

Rev. Growth (Yr)

-0.47%

Rev. Growth (Qtr)

13.27%

CSBR Earnings

Earnings (TTM)

3.0M

Earnings Growth (Yr)

-133.21%

Earnings Growth (Qtr)

76.24%

CSBR Profitability

EBT Margin

4.99%

Return on Equity

84.15%

Return on Assets

9.66%

Free Cashflow Yield

8.74%

CSBR Investor Care

Shares Dilution (1Y)

1.43%

Diluted EPS (TTM)

0.21

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	58.6M	56.9M	56.9M	0
2024	49.2M	50.2M	51.7M	53.6M
2023	53.7M	53.9M	52.7M	50.0M
2022	46.8M	49.1M	51.6M	54.1M
2021	39.2M	41.0M	42.7M	44.4M
2020	31.1M	32.1M	34.9M	37.4M
2019	24.3M	27.1M	27.6M	28.5M
2018	19.0M	20.2M	21.4M	22.9M
2017	14.5M	15.4M	16.8M	17.5M
2016	11.6M	11.2M	12.0M	13.5M
2015	8.1M	8.9M	9.8M	10.9M
2014	10.9M	11.6M	10.4M	9.9M
2013	7.9M	8.3M	9.2M	10.2M
2012	7.3M	7.2M	7.6M	7.3M
2011	0	6.9M	6.9M	7.7M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a dynamic analytic and visualization software that empowers cancer biologists to harness the power of computational science in a convenient and sophisticated tool. The company markets its products through internet, word of mouth, and sales force to patients and physicians. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

CEO	Dr. Ronnie Morris M.D.
WEBSITE	championsoncology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	230

Champions Oncology Inc Frequently Asked Questions

What is the ticker symbol for Champions Oncology Inc? What does CSBR stand for in stocks?

CSBR is the stock ticker symbol of Champions Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Champions Oncology Inc (CSBR)?

As of Wed Dec 03 2025, market cap of Champions Oncology Inc is 82.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CSBR stock?

You can check CSBR's fair value in chart for subscribers.

Is Champions Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether CSBR is over valued or under valued. Whether Champions Oncology Inc is cheap or expensive depends on the assumptions which impact Champions Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CSBR.

What is Champions Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, CSBR's PE ratio (Price to Earnings) is 28.07 and Price to Sales (PS) ratio is 1.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSBR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Champions Oncology Inc's stock?

In the past 10 years, Champions Oncology Inc has provided 0.035 (multiply by 100 for percentage) rate of return.